Development of a Second-Generation, In Vivo Chemical Probe for PIKfyve

We optimized our highly potent and cell-active chemical probe for phosphatidylinositol-3-phosphate 5-kinase (PIKfyve), SGC-PIKFYVE-1, resulting in compounds with improved potency and demonstrated stability. Use of an in-cell, kinome-wide selectivity panel allowed for confirmation of excellent in-cel...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry 2025-01
Main Authors: Min, Sophia M, Bashore, Frances M, Smith, Jeffery L, Havener, Tammy M, Howell, Stefanie, Li, Haoxi, Couñago, Rafael M, Popov, Konstantin I, Axtman, Alison D
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We optimized our highly potent and cell-active chemical probe for phosphatidylinositol-3-phosphate 5-kinase (PIKfyve), SGC-PIKFYVE-1, resulting in compounds with improved potency and demonstrated stability. Use of an in-cell, kinome-wide selectivity panel allowed for confirmation of excellent in-cell selectivity of our lead compound, , and another promising analogue, . Evaluation of the pharmacokinetic (PK) profiles of these two compounds revealed that both are well tolerated systemically and orally bioavailable. Coupled with its subnanomolar cellular potency and impressive selectivity in cells, the long half-life of makes it an ideal candidate for the evaluation of the consequences of PIKfyve inhibition . PIKfyve inhibition has been investigated clinically for indications including rheumatoid arthritis, Crohn's disease, COVID-19, and ALS using a single compound (apilimod), supporting the development of orthogonal PIKfyve inhibitors with stability.
ISSN:1520-4804
1520-4804
DOI:10.1021/acs.jmedchem.4c02531